A novel and simple method of screening compounds for interaction with DNA: A validation study

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 678, Issue 1, 2009, Pages 20-29

  Garas, Adel ^a   Webb, Elizabeth ^a   Pillay, Vinochani ^a   MacPhee, Donald ^a   Denny, William ^b   Zeller, Hilary ^a   Cotton, Richard ^a,c  

^a Genomic Disorders Research Centre   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antibiotic; Anticancer; Drug discovery; Environmental; Food; Genotoxicity

Indexed keywords

DNA; PERMANGANATE POTASSIUM;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA DETERMINATION; GENOTOXICITY; PRIORITY JOURNAL; SCREENING; ULTRAVIOLET SPECTROSCOPY;

ALKYLATING AGENTS; DNA DAMAGE; DRUG DISCOVERY; INTERCALATING AGENTS; MUTAGENICITY TESTS; MUTAGENS; POTASSIUM PERMANGANATE; PYRIMIDINES; SACCHAROMYCES CEREVISIAE;

BACTERIA (MICROORGANISMS);

EID: 68349125412     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2009.06.005     Document Type: Article

References (54)

1. In: Demeunynck M., Bailly C., and Wilson W.D. (Eds). DNA and RNA Binders: From Small Molecules to Drugs (2002), Wiley-VCH
2. Kramer P.J. Genetic toxicology. J. Pharm. Pharmacol. 50 (1998) 395-405
3. Snyder R. Business briefing. Future Drug Discov. 3 (2003) 68-71
4. C.T. Bui, R.G. Cotton, A. Bedir, Methods of detection of conformational change in a nucleic acid duplex by treatment with oxidising or reactive agent as a result of exposure to environmental or chemical conditions, 2001 (PCT/AU02/01259).
5. Bui C.T., and Cotton R.G. Comparative study of permanganate oxidation reactions of nucleotide bases by spectroscopy. Bioorg. Chem. 30 (2002) 133-137
6. Denny W.A., Atwell G.J., Baguley B.C., and Wakelin L.P. Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J. Med. Chem. 28 (1985) 1568-1574
7. Atwell G.J., Baguley B.C., Wilmanska D., and Denny W.A. Potential antitumor agents. 45. Synthesis, DNA binding and biological activity of triacridine derivatives. J. Med. Chem. 29 (1986) 69-74
8. Atwell G.J., Rewcastle G.W., Baguley B.C., and Denny W.A. Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 30 (1987) 664-669
9. Atwell G.J., Rewcastle G.W., Baguley B.C., and Denny W.A. Potential antitumor agents. 48. 3′-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity. J. Med. Chem. 30 (1987) 652-658
10. Baguley B.C., Denny W.A., Atwell G.J., Finlay G.J., Rewcastle G.W., Twigden S.J., and Wilson W.R. Synthesis, antitumor activity and DNA-binding properties of a new derivative of amsacrine (CI-921: NSC 343499). Cancer Res. 44 (1984) 3245-3252
11. Cain B.F., Atwell G.J., and Denny W.A. Potential antitumor agents. 16. 4′-(Acridin-9-ylamino)methanesulfonanilides. J. Med. Chem. 18 (1975) 1110-1117
12. Denny W.A., Twigden S.J., and Baguley B.C. Steric constraints for DNA binding and biological activity in the amsacrine series. Anticancer Drug Des. 1 (1986) 25-32
13. Baguley B.C., Ferguson L.R., and Denny W.A. DNA binding and growth inhibitory properties of a series of 2,7-di-alkyl-substituted derivatives of proflavine. Chemico-Biolog. Int. 42 (1982) 97-105
14. Deady L.W., Rodemann T., Zhuang L., Baguley B.C., and Denny W.A. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. J. Med. Chem. 46 (2003) 1049-1054
15. Spicer J.A., Gamage S.A., Finlay G.J., and Denny W.A. Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs. Bioorg. Med. Chem. 10 (2002) 19-29
16. Gamage S.A., Spicer J.A., Finlay G.J., Stewart A.J., Charlton P., Baguley B.C., and Denny W.A. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase-targeted anticancer drugs. J. Med. Chem. 44 (2001) 1407-1415
17. Bailly C., Cuthbert A.W., Gentle D., Knowles M.R., and Waring M.J. Sequence-selective binding of amiloride to DNA. Biochemistry 32 (1993) 2514-2524
18. Denny W.A. Acridine-4-carboxamides and the concept of minimal DNA intercalators. In: Demeunynck M., Bailly C., and Wilson W.D. (Eds). DNA and RNA Binders: From Small Molecules to Drugs (2002), Wiley-VCH 482-497
19. Lombardi P., and Crisanti A.A. Antimalarial activity of synthetic analogues of distamycin. Pharmacol. Ther. 76 (1997) 125-133
20. Martin J.C., Wartell R.M., and O'Shea D.C. Conformational features of distamycin-DNA and netropsin-DNA complexes by Raman spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 5483-5487
21. Delobel P., and Pradinaud R. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J. Antimicrob. Chemother. 51 (2003) 1319-1320
22. Bui C.T., Sam L.A., and Cotton R.G. UV-visible spectral identification of the solution-phase and solid-phase permanganate oxidation reactions of thymine acetic acid. Bioorg. Med. Chem. Lett. 14 (2004) 1313-1315
23. Ogino T., Hasegawa K., and Hoshino E. Kinetics of the permanganate oxidation of endo-dicyclopentadiene in nonaqueous organic solution. J. Org. Chem. 55 (1990) 2653-2656
24. Freeman F., Fuselier C.O., Armstead C.R., Dalton C.E., Davidson P.A., Karchesfski E.M., Krochman D.E., Johnson M.N., and Jones N.K. Permanganate ion oxidations. 13. Soluble manganese(IV) species in the oxidation of 2,4(1H,3H)-pyrimidinediones (uracils). J. Am. Chem. Soc. 103 (1981) 1154-1159
25. Albers W., Annila A., Goddard N.J., Patonay G., and Soini E. In: Gauglitz G., and Vo-Dinh T. (Eds). Handbook of Spectroscopy, vol. 2 (2003), Wiley 29
26. R. Brederhorst, R. Hintsche, A. Heuberger, Activated enzyme-linked detection systems for detecting and quantifying nucleic acids, antigens and other analytes, WO/2002/082078 (2002).
27. Besterman J.L., Elwell L.P., Blanchard S.G., and Cory M. Amiloride intercalates into DNA and inhibits DNA topoisomerase 11. J. Biolog. Chem. 262 (1987) 3352-13358
28. Webb M.R., and Ebeler S.E. Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem. J. 384 (2004) 527-541
29. Snyder R.D., and Gillies P.J. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen. 40 (2002) 266-276
30. Olaharski A.J., Mondrala S.T., and Eastmond D.A. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat. Res. 582 (2005) 79-86
31. Czeczot H., Tudek B., Kusztelak J., Szymczyk T., Dobrowolska B., Glinkowska G., Malinowski J., and Strzelecka H. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat. Res. 240 (1990) 209-216
32. Allison R.G., and Hahn F.E. Changes in superhelical density of closed circular deoxyribonucleic acid by intercalation of anti-R-plasmid drugs and primaquine. Antimicrob. Agents Chemother. 11 (1977) 251-257
33. Kantesaria P., and Marfey P. The effect of chlorpromazine on some properties DNA in solution. Physiol. Chem. Phys. 7 (1975) 53-67
34. Atwell G.J., Denny W.A., Clark G.R., O'Connor C.J., Matsuzawa Y., and Yoshikawa K. Mono-, bis- and tetra-acridine ligands: synthesis, X-ray structural determination and dynamic fluorescence microscope studies on the modification of the higher order structure of DNA. J. Phys. Org. Chem. 8 (1995) 597-604
35. BIBRA: an assessment of the carcinogenic and mutagenic potential of quinine hydrochloride by three short-term tests. Unpublished Report No. 259/l/79 (1979) from the British Industrial Biological Research Association, Carshalton, Surrey, England. Submitted to WHO by Cadbury Schweppes, Group Research, Reading, England.
36. Munzner R., and Renner H.W. Mutagenicity testing of quinine with submammalian and mammalian systems. Toxicology 26 (1983) 173-178
37. M. Richold, J.A. Allen, A. Williams, S.J. Ransome, Cell transformation test for carcinogenicity of quinine hydrochloride. Unpublished Report No. CBL 19/80810 (1981) from Huntingdon Research Centre, Huntingdon, Cambridgeshire, England. Submitted to WHO by Cadbury Schweppes, Group Research, Reading, England.
38. Matsuo M., Sasaki N., Saga K., and Kaneko T. Cytotoxicity of flavonoids toward cultured normal human cells. Biol. Pharm. Bull. 28 (2005) 253-259
39. Kier L.D., Brusick D.J., Auletta A.E., Von Halle E.S., Brown M.M., Simmon V.F., Dunkel V., McCann J., Mortelmans K., Prival M., Rao T.K., and Ray V. The Salmonella typhimurium/mammalian microsomal assay: a report of the U.S. environmental protection agency gene-tox program. Mutat. Res. 168 (1986) 69-240
40. W. Muller, Berenil: study of the mutagenic potential in strains of Salmonella typhimurium (Ames test) and Escherichia coli. Unpublished report No.88. 1425 (1989) from Pharma Research Toxicology and Pathology, Hoechst Aktiengesellschaft, Frankfurt, Germany. Submitted to WHO by Hoechst AG, Frankfurt, Germany.
41. Stauffert I., Paulini H., Steinmann U., Sippel H., and Estler C.J. Investigations on mutageni (1995) city and genotoxicity of pentamidine and some related tryanocidal diamidines. Mutat. Res. 245 (1990) 93-98
42. Connor T.H., and Trizna Z. Pentamidine isethionate is negative in tests for microbial mutagenicity and chromosomal breakage in vitro. Toxicol. Lett. 63 (1992) 69-74
43. Ferguson L.R., and Denny W.A. Microbial mutagenic effects of the DNA minor groove binder pibenzimol (Hoechst 33258) and a series of mustard analogues. Mutat. Res. 329 (1995) 19-27
44. Mazza G., Mondello C., and Nuzzo F. Determination of mutagenic and genotoxic activity of the antibiotic distamycin A. G. Ital. Chemioter. 30 (1983) 39-52
45. Freyer M.W., Buscaglia R., Cashman D., Hyslop S., Wilson W.D., Chaires J.B., and Lewis E.A. Binding of netropsin to several DNA constructs: evidence for at least two different 1:1 complexes formed from an -AATT-containing ds-DNA construct and a single minor groove binding ligand. Biophys. Chem. 126 (2007) 186-196
46. Singh B., and Gupta R.S. Species-specific differences in the toxicity and mutagenicity of the anticancer drugs mithramycin, chromomycin A3, and olivomycin. Cancer Res. 45 (1985) 2813-2820
47. Nguewa P.A., Fuertes M.A., Cepeda V., Iborra S., Carrion J., Valladares B., Alonso C., and Perez J.M. Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem. Biodivers. 2 (2005) 1387-1400
48. Munchausen L.L. The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA. Proc. Natl. Acad. Sci. U.S.A. 71 (1974) 4519-4522
49. Novakova O., Vrana O., Kiseleva V.I., and Brabec V. DNA interactions of antitumor platinum(IV) complexes. Eur. J. Biochem. 228 (1995) 616-624
50. van Delft J.H.M., van Agen E., van Breda S.G.J., Herwijnen M.H., Staal Y.C.M., and Kleinjans J.C.S. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25 (2004) 1265-1276
51. Himes R.H., Kersey R.N., Heller-Bettinger I., and Samson F.E. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 36 (1976) 3798-3802
52. Konopacka M., and Rogolinski J. Thiamine prevents X-ray induction of genetic changes in human lymphocytes in vitro. Acta Biochim. Pol. 51 (2004) 839-843
53. Wink M., Schmeller T., and Latz-Bruning B. Modes of action of allelochemical alkaloids: interaction with neuroreceptors, DNA and other molecular targets. J. Chem. Ecol. 24 (1998) 1881
54. Cahill P.A., Knight A.W., Billinton N., Barker M.G., Walsh L., Keenan P.O., Williams C.V., Tweats D.J., and Walmsley R.M. The GreenScreen genotoxicity assay: a screening validation programme. Mutagenesis 19 (2004) 105-119